Skip to main content

TCG Crossover — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

81
Companies
$14.3B
Total invested
$176.4M
Avg. check
12
Industries
Biotechnology 23Health Care 17Therapeutics 16Medical 12Pharmaceutical 7Biopharma 6+6 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 49–72 of 81
Perspective Therapeutics
February 2026

Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.

Health Care · Seattle$175.0M Post Ipo Equity
CORXEL Pharmaceuticals
January 2026

CORXEL Pharmaceuticals is a biotechnology company that develops science and medicines for underserved patients.

Biotechnology · Shanghai$287.0M Series D
Mirador Therapeutics
January 2026

Mirador Therapeutics develops precision medicines for immune-mediated diseases.

Biotechnology · San Diego$250.0M Series B
Century Therapeutics
January 2026

Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.

Biotechnology · Philadelphia$135.0M Post Ipo Equity
Beacon Therapeutics
January 2026

Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.

Biotechnology · Alachua$75.0M Series C
Mirum Pharmaceuticals
December 2025

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

Biotechnology · Foster City$68.5M Post Ipo Equity
Structure Therapeutics
December 2025

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Biotechnology · South San Francisco$747.5M Post Ipo Equity
Cogent Biosciences
November 2025

Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.

Biotechnology · Waltham$200.0M Post Ipo Debt
Rapt Therapeutics
October 2025

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

Biotechnology · South San Francisco$250.0M Post Ipo Equity
ADC Therapeutics
October 2025

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Biopharma · Lausanne$60.0M Post Ipo Equity
Affinia Therapeutics
October 2025

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Biotechnology · Waltham$40.0M Series C
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Maze Therapeutics
September 2025

Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.

Biopharma · South San Francisco$150.0M Post Ipo Equity
Mineralys Therapeutics
September 2025

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$287.5M Post Ipo Equity
Korsana Biosciences
September 2025

Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.

Biopharma · Waltham$150.0M Series A
Plexium
August 2025

Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.

Biotechnology · San Diego$60.1M Series C
Abivax
July 2025

Abivax develops medicines that alter the body's natural immune system mechanisms.

Biotechnology · Paris$747.5M Post Ipo Equity
Arbor Biotechnologies
March 2025

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

Artificial Intelligence (AI) · Cambridge$73.9M Series C
ADARx Pharmaceuticals
February 2025

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Biotechnology · San DiegoSeries Unknown
Inhibrx
January 2025

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

Biotechnology · La Jolla$150.0M Post Ipo Debt
ADCendo
November 2024

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

Biotechnology · Copenhagen$135.0M Series B
Avalo Therapeutics
November 2024

Avalo Therapeutics is a clinical-stage biopharmaceutical company.

Biotechnology · Rockville$69.4M Post Ipo Equity
Vicebio
September 2024

Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.

Biotechnology · London$100.0M Series B
Pathalys Pharma
August 2024

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.

Biopharma · Raleigh$105.0M Series B

Where TCG Crossover invests

Biotechnology23
Health Care17
Therapeutics16
Medical12
Pharmaceutical7
Biopharma6

About TCG Crossover's portfolio

How many companies has TCG Crossover invested in?▸

TCG Crossover has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does TCG Crossover invest in?▸

TCG Crossover's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 12 different industry categories.

What is TCG Crossover's largest investment?▸

Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post Ipo Equity round. TCG Crossover's total known invested capital is $14.3B.

What is the average investment size for TCG Crossover?▸

TCG Crossover's average investment size is $176.4M across its portfolio of 81 companies.

What are TCG Crossover's most recent investments?▸

Recent TCG Crossover portfolio additions include Perspective Therapeutics, CORXEL Pharmaceuticals, Mirador Therapeutics, Century Therapeutics, Beacon Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 81 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →